Manufacturing‐dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid A analog development-Reference-Cited by-同舟云学术

Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

Published:2022-09-12 Issue:11 Volume:15 Page:2625-2639
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Steeghs Neeltje¹,Hansen Aaron R.²,Hanna Glenn J.³⁴,Garralda Elena⁵,Park Haeseong⁶,Strauss James⁷,Adam Michael⁸,Campbell Gossett⁸,Carver Jennifer⁸,Easton Rachael⁸,Mays Katherine⁸,Skrdla Peter⁸,Struemper Herbert⁹,Washburn Michael L.⁸^ORCID,Matheny Christopher⁸,Piha‐Paul Sarina A.¹⁰

Affiliation:

1. Netherlands Cancer Institute Amsterdam The Netherlands

2. Princess Margaret Cancer Centre Toronto Ontario Canada

3. Northwest Medical Specialists Tacoma Washington State USA

4. Dana‐Farber Cancer Institute Boston Massachusetts USA

5. Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Barcelona Spain

6. Washington University St Louis Missouri USA

7. Mary Crowley Cancer Research Center Dallas Texas USA

8. GlaxoSmithKline Collegeville Pennsylvania USA

9. GlaxoSmithKline Durham North Carolina USA

10. University of Texas MD Anderson Cancer Center Houston Texas USA

Funder